NDAORALTABLET
Approved
Mar 2021
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
3
Data completeness
5/8 — Partial
PONVORY (ponesimod) by Vanda Pharmaceuticals is sphingosine 1-phosphate receptor modulators [moa]. First approved in 2021.
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PONVORY (ponesimod) is an oral sphingosine 1-phosphate (S1P) receptor modulator approved in March 2021 for treating relapsing forms of multiple sclerosis (RRMS). It works by sequestering lymphocytes in lymphoid tissues, reducing their migration to the central nervous system and decreasing neuroinflammation.
$0.008BPart D
Peak16.3 years to LOEEarly peak-stage asset from mid-size sponsor Vanda Pharmaceuticals with modest current uptake; commercial team likely focused on market penetration and competitive positioning in the S1P modulator class.
Mechanism of Action
Sphingosine 1-Phosphate Receptor Modulators
Pharmacologic Class:
Sphingosine 1-phosphate Receptor Modulator
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis
Started Feb 2026
300 enrolled
Moderate-to-severe Chronic Plaque Psoriasis
A Study of Ponesimod in Healthy Adult Participants
Started Oct 2022
28 enrolled
Healthy
A Study of Ponesimod in Healthy Adult Participants Receiving Propranolol at Steady State
Started Mar 2019
52 enrolled
Healthy
Career Relevance
PONVORY roles primarily sit in commercial and medical affairs functions at Vanda Pharmaceuticals, a mid-size specialty pharma company. Career growth depends on market penetration success against established S1P competitors and the company's overall portfolio strategy.
Worked on PONVORY at Vanda Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.